Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ABIOMED'S TEMPORARY ARTIFICIAL HEART SYSTEM REACHES 1,000 PATIENT MILESTONE; BVS-5000 IN MORE THAN 100 U.S. MEDICAL CENTERS.


DANVERS, Mass.--(BUSINESS WIRE)--April 27, 1995-- ABIOMED, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:ABMD ABMD areal bone mineral density
ABMD AEGIS Ballistic Missile Defense (US Navy)
ABMD Advanced Ballistic Missile Defense
) today announced that a twenty-two year old student, discharged April 25th from Boston's Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. , was the one thousandth patient to be supported with the BVS-5000 heart support system. This patient had a flu-like infection that developed into viral myocarditis Myocarditis Definition

Myocarditis is an inflammatory disease of the heart muscle (myocardium) that can result from a variety of causes. While most cases are produced by a viral infection, an inflammation of the heart muscle may also be instigated by
 and resulted in severe, life-threatening heart failure. She was maintained on full BVS BVS Biblioteca Virtual em Saúde (Brazil)
BVS Bureau of Vital Statistics
BVS Brethren Volunteer Service (Church of the Brethren)
BVS Boston Vegetarian Society (Cambridge, MA) 
(R) support by Dr. Gregory S. Couper, Director of the Cardiac Surgical I.C.U. To save her life, BVS support to both sides of her heart was required for 11 days. This gave her heart time to recover from the infection and for the patient to make a complete recovery.

The BVS-5000, the initial product of ABIOMED's Cardiovascular division, was the first such device to receive FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 approval in November, 1992. It is the only approved device capable of supporting both the right and left sides of the failing heart. It is intended for temporary use for patients in postcardiotomy shock. The BVS continues to save lives and is becoming the standard of care at many leading medical centers. By the end of the Company's fiscal year on March 31, 1995, the second fiscal year since FDA approval, the BVS-5000 had been installed in over 100 hospitals in the U.S.

Based in Danvers, Massachusetts, ABIOMED, Inc. develops, manufactures and markets innovative cardiovascular, medical and dental products and is a leader in the research and development of heart support systems.

CONTACT: John F. Thero

Chief Financial Officer

Kristin T. Hurley

Executive Assistant

(508) 777-5410 Ext. 100

or

Betsy Brod/Alex Gleeson

Media Contact:

Lee Foley

Morgen-Walke Associates

(212) 850-5600
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 27, 1995
Words:276
Previous Article:Canhorn Chemical Corporation lists on the Toronto Stock Exchange.
Next Article:Moody's confirms Georgetown University's ratings; Review in conjunction with concerns associated with District of Columbia Medicaid.
Topics:



Related Articles
ABIOMED's temporary artificial heart system reaches 200 U.S. medical center milestone.
Abiomed announces second quarter results; Quarter and year-to-date earnings increase by over 350%.
Abiomed Announces Collaborative Agreement With Jewish Hospital and the University of Louisville to Prepare for Human Trials of Its Battery-Powered...
ABIOMED's BVS-5000 in the 100th Heart Transplant Center in the USA.
ABIOMED Announces French Regulatory Approval of the AB5000 Circulatory Support System; ABIOMED to Open French Office for Direct Sales and Clinical...
Abiomed Announces Participation in AdvaMed's ''Profiles in Progress You Can See'' Events; Abiomed's Ventricular Assist Devices for Acute Heart...
Abiomed Announces Heart Recovery Technology Presentations at International Society of Rotary Blood Pumps Meeting.
ADDING MULTIMEDIA Abiomed Receives FDA Approval of The AbioCor(R), the World's First Completely Self-Contained, Implantable Artificial Heart; AbioCor...
Abiomed Expands Availability of Impella Circulatory Support Technologies with Regulatory Approvals in India.
Abiomed Announces Australian Regulatory Approval of Impella Circulatory Support Technologies.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles